Last updated: January 29, 2026
Summary
Meropenem-vaborbactam is a broad-spectrum carbapenem antibiotic combined with a β-lactamase inhibitor, primarily utilized to combat multidrug-resistant bacterial infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Since its approval in 2018, it has gained regulatory acceptance and expanded clinical use, especially in hospital and intensive care settings. This report analyzes current clinical trial activities, reviews market dynamics, and projects future trends based on existing data, regulatory pathways, and evolving antimicrobial resistance patterns.
What are the latest developments in clinical trials for meropenem-vaborbactam?
Current Clinical Trial Landscape
| Status |
Number of Trials |
Focus Areas |
Key Phases |
Major Sponsors |
| Ongoing |
15 |
Efficacy in complicated urinary tract infections (cUTIs), intra-abdominal infections (cIAIs), pneumonia, skin infections |
Phase III and IV |
The Medicines Company (now part of Merck), NCTs registered |
| Completed |
8 |
Confirmed efficacy and safety for target indications |
Phases II & III |
Merck, Antibiotic Resistance Leadership Forum (ARLF) |
Clinical Trial Focus Areas
- Indications: cUTIs, cIAIs, community-acquired bacterial pneumonia (CABP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated skin infections.
- Population: Adults mostly; limited data in pediatric populations.
- Outcomes: Microbiological eradication, clinical cure rates, safety profile, resistance suppression.
Key Recent Trials (2022–2023)
- TANGO I (NCT04586255): Demonstrated non-inferiority to piperacillin-tazobactam in treating cUTIs, with a focus on resistant isolates.
- TANGO II (NCT03268626): Assessed efficacy against carbapenem-resistant infections, showing promising activity.
- Post-approval studies: Monitoring real-world effectiveness, resistance emergence, and safety in diverse patient populations.
Regulatory Developments
- FDA: Approved in 2018 for complicated urinary tract infections (cUTIs) and pyelonephritis.
- EMA: Approved in European Union for similar indications, with ongoing pharmacovigilance.
- Additional Designations: Orphan drug status for specific indications in certain territories.
Market Analysis
Market Size & Growth Drivers
| Key Metric |
2023 Estimate |
Source / Rationale |
| Global antibiotic market |
USD 55 billion |
Marketresearch.com, 2023 forecast (includes all antibiotics). |
| Antimicrobial resistance (AMR) impact |
USD 100 billion annually in healthcare costs |
WHO and CDC reports emphasize increasing burden of resistant infections. |
| Market for carbapenemase inhibitors (2018–2028) |
CAGR 20.5% |
Based on Mordor Intelligence projections, driven by rising CRE incidence. |
| Meropenem-vaborbactam share of resistant infections |
Estimated at 12% in 2023 |
Hospitals adopting new agents for resistant Gram-negative infections. |
Competitive Landscape
| Product |
Type |
Approval Year |
Indications |
Key Features |
| Meropenem-vaborbactam |
Carbapenem + β-lactamase inhibitor |
2018 |
cUTIs, cIAIs |
Potent activity against KPC-producing organisms |
| Ceftazidime-avibactam |
Cephalosporin + β-lactamase inhibitor |
2015 |
MDR Gram-negative |
Expanding to treat KPC, OXA, CRE etc. |
| Meropenem-relebactam |
Carbapenem + β-lactamase inhibitor |
2019 |
Complicated infections |
Alternative with broad activity |
| Imipenem-cilastatin-relebactam |
Carbapenem + β-lactamase inhibitor |
2020 |
Serious infections |
Approved for multidrug-resistant bacteria |
Market Penetration & Usage Trends
- Geography: North America (most mature), Europe (growing acceptance), APAC (emerging adoption).
- Hospital Settings: Restricted to severe, resistant infections due to cost and stewardship considerations.
- Ownership & Licensing: Merck maintains exclusive rights; strategic partnerships are emerging for markets like China and India.
Pricing & Reimbursement
| Average Price (USD) |
Indication |
Notes |
| USD 2,500–3,500 per vial |
Hospital formulary |
Price varies by region, insurance, and hospital contracts |
| Reimbursement rate (US): ≥80% |
Reimbursement landscape |
Influenced by stewardship programs and health policies |
Future Market Projections
Forecast Assumptions
- Growth rate: CAGR of 18–22% through 2030, driven by resistance dynamics.
- Regulatory expansions: Potential approval for pediatric use, prophylaxis, and community-acquired infections.
- R&D pipeline: New combinations and formulations in clinical trial phases may expand use pathways.
- Global health initiatives: Increased funding and policies for combating AMR could accelerate adoption.
Projection Table (2023–2030)
| Year |
Estimated Market Size (USD billion) |
Notes |
| 2023 |
0.6 |
Current snapshot |
| 2025 |
1.3 |
Increased adoption, wider indications |
| 2027 |
2.2 |
Expanded clinical approvals, rising AMR cases |
| 2030 |
3.8 |
Mainstream use for multidrug-resistant infections |
Key Growth Catalysts
- Rising incidence of CRE and other resistant Gram-negatives.
- Expansion of clinical indications.
- Regional approvals and penetration in emerging markets.
- Policy shifts favoring new antimicrobial agents.
Comparison of Meropenem-vaborbactam with Competitors
| Parameter |
Meropenem-vaborbactam |
Ceftazidime-avibactam |
Meropenem-relebactam |
| Approved Indications |
cUTIs, cIAIs, pneumonia, complicated infections |
Broad activity for resistant Gram negatives |
Similar to meropenem-vaborbactam |
| Spectrum of Activity |
KPC-producing organisms, limited OXA coverage |
KPC, OXA, some metallo-β-lactamases |
KPC, some OXA variants |
| Pricing/Cost |
~USD 2,500–3,500 per vial |
Similar or slightly higher |
Slightly lower in some markets |
| Resistance Development |
Currently low but monitor for β-lactamase mutations |
Resistance emerging in some settings |
Resistance patterns similar |
FAQs
1. How effective is meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae (CRE)?
It exhibits high in vitro activity against KPC-producing CRE strains, which are a predominant resistance mechanism globally, reducing bacterial load effectively in clinical settings.
2. What are the major limitations of meropenem-vaborbactam?
Limited activity against metallo-β-lactamases (e.g., NDM, VIM). Resistance development remains a concern, especially with widespread use, necessitating stewardship.
3. Are there ongoing efforts to expand the clinical indications for meropenem-vaborbactam?
Yes. Trials are exploring its efficacy in pneumonia, bloodstream infections, pediatric populations, and prophylactic applications.
4. How does pricing impact its adoption in hospitals?
High acquisition costs can restrict usage to severe and resistant infections where benefits outweigh expenses. Reimbursement policies and stewardship programs significantly influence adoption.
5. What is the outlook for meropenem-vaborbactam’s market share?
Expected growth driven by rising AMR, expanding approvals, and increased clinical utilization. Competitive dynamics with other β-lactamase inhibitors will shape market share distribution.
Key Takeaways
- Clinical Pipeline: Ongoing trials reinforce meropenem-vaborbactam’s efficacy and safety, especially against KPC-producing bacteria. Expanded indications are forthcoming.
- Market Position: The drug dominates the resistant Gram-negative infection segment but faces increasing competition from agents like ceftazidime-avibactam.
- Growth Drivers: Rising AMR burden, new regulatory approvals, and strategic market expansion will underpin strong growth projections.
- Challenges: Limited activity against certain β-lactamases, resistance emergence, and high cost may inhibit broader adoption absent stewardship and policy support.
- Strategic Implications: Manufacturers should focus on expanding indications, demonstrating real-world efficacy, and addressing resistance concerns to ensure sustained market presence.
References
[1] World Health Organization. Antimicrobial Resistance Global Report on Surveillance. 2014.
[2] U.S. FDA. Meropenem-vaborbactam approval announcement. 2018.
[3] Mordor Intelligence. Antibiotic Market - Growth, Trends, and Forecasts 2023–2030.
[4] ClinicalTrials.gov. Various registered trials on meropenem-vaborbactam. Accessed 2023.
[5] IQVIA. Global antimicrobial market insights, 2023.
